Thermo Fisher Scientific raised its full-year 2026 organic growth guidance to approximately 4% at the Morgan Stanley Global Healthcare Conference on September 15, 2026. Management stated the business is entering a stronger phase driven by improving demand and solid execution.
Current orders are outpacing revenue, suggesting continued operational strength heading into 2027. This optimistic forecast follows a second quarter that delivered the company's fastest organic growth pace since 2021.
Analysts currently rate the stock a strong buy in response to the improved guidance and healthcare sector momentum. The company also recently launched Precure, LLC, a partnership with Mayo Clinic focused on early disease detection.